T20742 |
TG-89
|
936091-56-4
|
98%
|
|
TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cer...
|
T16995 |
TAS05567
|
1429038-15-2
|
98%
|
|
TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM). TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, ...
|
T10823 |
Trans-Pralsetinib
|
2097132-93-7
|
98%
|
|
trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET) extracted from patent US20170121312A1 (Compound Example 129).
|
T14928 |
Agerafenib hydrochloride
|
1227678-26-3
|
98%
|
|
Agerafenib hydrochloride is a highly potent inhibitor of BRAFV600E (Kd: 14 nM).
|
T12598 |
Pz-1
|
1800505-64-9
|
98%
|
|
Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.
|
T4301 |
AD80
|
1384071-99-1
|
98%
|
|
AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.
|
T1792 |
Regorafenib
|
755037-03-7
|
98%
|
|
Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor (IC50s: 1.5/2.5/4.2/7/13/22 nM for RET/C-RAF/VEGFR2/c-Kit/VEGFR1/PDGFRβ).
|
T67779 |
Compound TPX-0046
|
2411115-73-4
|
98%
|
|
Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.
|
T62285 |
Enbezotinib
|
2359649-81-1
|
98%
|
|
Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.
|
T8222 |
Selpercatinib
|
2152628-33-4
|
98%
|
|
Selpercatinib is a tyrosine kinase inhibitor with antineoplastic properties(IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), r...
|
T8467 |
RET V804M-IN-1
|
2414909-94-5
|
98%
|
|
RET V804M-IN-1 is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).
|
T2586 |
Cabozantinib
|
849217-68-1
|
98%
|
|
Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50s: 0.035, 1.3, 4.6, 7 and 11.3 nM).
|
T6920 |
ON123300
|
1357470-29-1
|
98%
|
|
ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
|
T2620 |
G-749
|
1457983-28-6
|
98%
|
|
G-749, a new-type FLT3 inhibitor, exhibits effective and sustained inhibition of the FLT3 wild type and mutants.
|
T2070 |
Agerafenib
|
1188910-76-0
|
98%
|
|
CEP-32496 is a highly potent inhibitor of BRAF.
|
T3065 |
TG101209
|
936091-14-4
|
98%
|
|
TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.
|
T9445 |
Vepafestinib
|
2129515-96-2
|
98%
|
|
Vepafestinib is a RET inhibitor with potential antineoplastic activity[1].
|
T2516 |
Amuvatinib
|
850879-09-3
|
98%
|
|
Amuvatinib is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.
|
T0520 |
Lenvatinib
|
417716-92-8
|
98%
|
|
Lenvatinib is a Kinase Inhibitor. The mechanism of action of lenvatinib is as a Receptor Tyrosine Kinase Inhibitor.
|
T2094 |
Danusertib
|
827318-97-8
|
98%
|
|
Danusertib is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may ...
|